MS Speaks

An informative news story about Ocrevus from McGill University in Canada (May 11, 2018), "Developing the first effective drug for progressive MS":


http://publications.mcgill.ca/medenews/2018/05/10/developing-the-first-effective-drug-for-progressive-ms/


This part is something I haven't seen mentioned much elsewhere:

It should be noted that clinical data came from patients between the ages of 18 and 55.
“It’s not clear how well ocrelizumab works in older people who have had progressive multiple sclerosis for a long time,” cautions Dr. Arnold [a neurologist who worked in the development of ocrelizumab], adding that research continues.
The Multiple Sclerosis Society of Canada notes that “the safety and efficacy of ocrelizumab outside of the age range of 18 to 55 is unknown.” The Society advises older patients who are interested in ocrelizumab to consult their neurologist.